Awarded contract

NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.

Details

Value
£56
Topic
Pharmaceutical products
Published
23 February 2021

Tender description

CM/PHR/20/5591/01 - Midlands and East, Branded Medicines – Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/20/5591/02 - Midlands and East Branded Medicines – Annual Tranche, Cytokine Modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 monthsCM/PHR/20/5591/03 – Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021CM/PHR/20/5591/04 – Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021 Lot 1: Lot 1: Midlands and East (MAE) Tranche B CM/PHR/20/5591/01 - NHS Framework for the Midlands and East, Branded Medicines – Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: Lot 2: Midlands and East Cytokine Modulators and other monoclonal antibodies CM/PHR/20/5591/02 - NHS Framework for the Midlands and East Branded Medicines – Annual Tranche, Cytokine Modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: Lot 3: (LNW) – Interleukin Inhibitors, JAK Inhibitors, Migraine & Asthma CM/PHR/20/5591/03 – NHS Framework agreement for the supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 4: Lot 4: (SOFE) – Interleukin Inhibitors, JAK Inhibitors, Migraine & Asthma CM/PHR/20/5591/04 – NHS Framework agreement for the supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Timeline

  1. Completed: Award date25 January 2021
  2. Completed: Award published23 February 2021
    Current notice

About the buyer

NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.

AI insights

  • Is there a preferred supplier?
  • What are the buyers pain points?
  • What has the buyer previously procured?
  • What are the key requirements?
Sign-up to enrich

Decision makers

Connect with the people behind this procurement.

Contact nameJob titlePhone numberWork email
Head of Procurement+44 •••• ••••••
Commercial Director+44 •••• ••••••
Procurement Manager+44 •••• ••••••
Category Lead+44 •••• ••••••
Senior Buyer+44 •••• ••••••
Contracts Manager+44 •••• ••••••

6 similar open tenders

See more open tenders related to Pharmaceutical products.

Explore all open tenders

Finding public sector work shouldn't be hard

Make your next tender search effortless with Stotles. Set up alerts, find decision maker contacts and never miss a good-fit opportunity again.